CEOs are great talkers, they tell you what you want to hear. Thinking that DX1 manufacturing success will lead to bringing in non dilutive cash for DX3 is so incredibly wishful.
Also I’m not usually one to correct grammar but is there a reason you‘ve been spelling sporadic wrong for the last 12 months? Am I missing something?
Ann: Presentation to highlight broader potential of Deoxymabs, page-67
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $1.336K | 167K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8034700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1996944 | 7 |
View Market Depth
| Last trade - 10.20am 24/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |